Results

• All
• Video
• Audio
• Images

• Most recent

1–1 of 1 result for Benjamin Bakall

• 

  One Year Follow-Up in a Phase ½ Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa

  Benjamin Bakall, MD, PhD

  Updates from the Field

  2024